Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) Patents (Class 424/93.2)
  • Patent number: 11352411
    Abstract: Disclosed are a fusion peptide of CD4 helper T cell epitopes, a nucleic acid encoding the same and an immunogenic composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope and an influenza virus epitope. The epitope fusion peptide can substantially improve the level of cellular immune response to a target immunogen, particularly a weak immunogen, and is an effective means for overcoming the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen, and is suitable for efficiently enhancing the efficacy of vaccine.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: June 7, 2022
    Assignee: Vacdiagn Biotechnology Co., Ltd
    Inventors: Jianqing Xu, Yang Huang, Xiaoyan Zhang
  • Patent number: 11344589
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: May 31, 2022
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Takafumi Nakamura, Hajime Kurosaki, Motomu Nakatake
  • Patent number: 11344008
    Abstract: A method of producing a non-erythroid protein in erythrocytes of a transgenic animal using an erythroid-specific promoter includes synthesizing an erythroid-specific globin gene promoter and globin gene locus control region and cloning the promoter and the globin gene locus control region and a gene encoding a non-erythroid protein into a vector to obtain a transgene; introducing the transgene in pronuclear embryos collected from a mammalian animal in vitro; transplanting the pronuclear embryos containing the transgene into oviduct of a female recipient of the mammalian animal to obtain a transgenic animal which then expresses the non-erythroid protein in progenitor cells of erythrocytes; and collecting blood from the transgenic animal and isolating the non-erythroid protein from the erythrocytes.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: May 31, 2022
    Inventors: Hai Xing Chen, Hong Yang Wang, Zhongtian Qi
  • Patent number: 11332502
    Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 17, 2022
    Assignees: University of Florida Research Foundation, Incorporated, The UAB Research Foundation
    Inventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Nicholas Muzyczka, Hector Ruben Mendez-Gomez, Paul D. Gamlin
  • Patent number: 11331373
    Abstract: Methods and compositions using a nucleic acid molecule encoding an atonal-associated factor in combination with a co-transcription factor and/or inhibitor of a gene silencing complex to change the sensory perception of an animal are described.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 17, 2022
    Assignee: St. Jude Children's Research Hospital
    Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Wanda Layman
  • Patent number: 11318209
    Abstract: There is no specific cure for chronic kidney disease (CKD), which affects one in every ten adults. The unmet medical need has created significant interest in regenerative therapeutic approaches. Described herein is a radically new and innovative therapeutic approach identified by characterizing a novel mechanism of renal tissue repair and its role in glomerular injury. By targeting this mechanism in CKD, significant therapeutic benefit supported by rapid cellular remodeling of kidney tissues, coincident with structural and functional nephron regeneration. Methods and compositions for achieving the described therapeutic approach are fundamentally different from existing strategies.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: May 3, 2022
    Assignee: MACULA DENSA CELL LLC
    Inventor: Janos Peti-Peterdi
  • Patent number: 11311632
    Abstract: Provided are compositions and methods for inducing expression of human beta-globin in erythrocytes for use in prophylaxis and/or therapy of a hemoglobinopathy in an individual. The method generally entails introducing into CD34+ cells a poly-nucleotide encoding: i) a 5? long terminal repeat (LTR) and a self-inactivating 3? LTR; ii) at least one polyadenylation signal; iii) at least one promoter; iv) a globin gene locus control region (LCR); v) an ankyrin insulator element (Ank); vi) a Woodchuck Post-Regulatory Element (WPRE) configured such that the WPRE does not integrate into a target genome; and vii) a sequence that is a reverse complement of a sequence encoding human beta-globin, and can include beta-globin that has a PT87Q mutation. Intron 2 of the beta globin gene can be a complete intron. Modified erythrocyte progenitor cells, recombinant vectors and virions comprising recombinant polynucleotides, and methods of making the vectors and virions are included.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: April 26, 2022
    Assignees: CORNELL UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Stefano Rivella, Laura Breda, Alisa Dong, Gerd Blobel, Wulan Deng
  • Patent number: 11291693
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: April 5, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet, Adam Fisher
  • Patent number: 11284607
    Abstract: The invention provides for transgenic donor animals (e.g., pigs) whose cells, tissues and organs have a better long-term survival when transplanted into a human patient. The transgenic donor animal carries one or more human transgenes which is expressed only when the endogenous gene of the donor animal is knocked out shortly before a graft is harvested for transplantation. This “genetic switch” allows the donor animal to remain healthy during the majority of its lifetime, while still allowing expression of the human transgene for optimal transplant tolerance in a human recipient. The transgene may encode a cytokine receptor, an adhesion molecule, or a complement regulatory protein.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: March 29, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Megan Sykes
  • Patent number: 11279954
    Abstract: Provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding TH is linked to the nucleotide sequence encoding CH1 such that they encode a fusion protein TH-CH1. Also provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding AADC is linked to the nucleotide sequence encoding TH such that they encode a fusion protein AADC-TH or TH-AADC. Further provided is a viral vector comprising such nucleotide sequences and its use in the treatment and/or prevention of Parkinson's disease.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 22, 2022
    Assignee: Oxford BioMedica (UK) Ltd.
    Inventors: Kyriacos A. Mitrophanous, Scott Ralph, Hannah Stewart, Alan John Kingsman
  • Patent number: 11278593
    Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 22, 2022
    Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: Matthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'Neill
  • Patent number: 11274139
    Abstract: The present invention pertains to inter alia therapeutic delivery vesicles, for instance exosomes or microvesicles, comprising polypeptide constructs, methods for producing said therapeutic delivery vesicles, pharmaceutical compositions and medical uses thereof. The therapeutic polypeptide constructs comprised in the extracellular delivery vesicles enable sequestering target molecules of interest, to treat e.g. neuro-inflammatory diseases and cancer.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 15, 2022
    Assignee: Evox Therapeutics Ltd
    Inventors: Samir El Andaloussi, Oscar Wiklander, Joel Nordin, Edvard Smith, Karl-Henrik Grinnemo, Oscar Simonson
  • Patent number: 11266726
    Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 8, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Baylor College of Medicine
    Inventors: Lauren V. Wood, Brenda D. Roberson, Jay A. Berzofsky, John C. Morris, Jason C. Steel, Masaki Terabe, Malcolm K. Brenner
  • Patent number: 11260134
    Abstract: Provided is a nucleic acid strand that can efficiently deliver an antisense oligonucleotide into the body, particularly a nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein the first nucleic acid strand includes a base sequence that is capable of hybridizing with at least a portion of a target transcription product, and exerts an antisense effect on the target transcription product; the second nucleic acid strand includes a complementary region having a base sequence complementary to the first nucleic acid strand and at least one overhang region located on the 5? and/or 3? side of the complementary region; and the first nucleic acid strand is annealed to the complementary region in the second nucleic acid strand.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 1, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori Yokota, Kotaro Yoshioka
  • Patent number: 11253612
    Abstract: A suspension useful for AAV9-mediated intrathecal and/or systemic delivery of an expression cassette containing a hIDS gene is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating Hunter syndrome and the symptoms associated with Hunter syndrome.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: February 22, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christian Hinderer, James M. Wilson
  • Patent number: 11254918
    Abstract: Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 22, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Novome Biotechnolooies, Inc.
    Inventors: Justin L. Sonnenburg, Weston R. Whitaker, Elizabeth Stanley, William C. DeLoache
  • Patent number: 11253608
    Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 22, 2022
    Assignee: EPICENTRX, INC.
    Inventors: Christopher Larson, Bryan Oronsky, Tony R. Reid
  • Patent number: 11236402
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 1, 2022
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Patent number: 11230719
    Abstract: The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: January 25, 2022
    Assignee: DENOVO BIOPHARMA LLC
    Inventors: Harry E. Gruber, Douglas J. Jolly, Amy H. Lin, Joan M. Robbins, Derek G. Ostertag
  • Patent number: 11219651
    Abstract: A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: January 11, 2022
    Assignee: The University of Tokyo
    Inventors: Tomoki Todo, Hiroshi Fukuhara
  • Patent number: 11213534
    Abstract: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve ?-adrenergic responsiveness.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: January 4, 2022
    Assignees: The University of Cincinnati, The General Hospital Corporation
    Inventors: Roger J. Hajjar, Federica del Monte, Evangelia Kranias
  • Patent number: 11203761
    Abstract: The present disclosure provides engineered Vibrio sp. organisms. The organisms can be engineered to have an altered Chromosome II so that the altered Chromosome II can be used in Vibrio sp. and other organisms for the cloning or amplification of nucleic acid molecules and for the expression and production of proteins and peptides in a Vibrio sp. organism. One or more genetic elements have been deleted from Chromosome II and/or relocated from Chromosome II to Chromosome I. The engineered Vibrio sp. organisms of the invention can also have signal sequences fused to proteins or peptides to be secreted from the cell. In some embodiments the engineered Vibrio sp. organisms can have sequences that enable them to retain viability after incubation at low temperatures.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 21, 2021
    Assignee: Codex DNA, Inc.
    Inventors: Matthew T Weinstock, Christopher M. Wilson
  • Patent number: 11191847
    Abstract: Compositions for the treatment of hemophilia B are provided. In certain embodiments, the composition is a recombinant adeno-associated virus (rAAV) comprising an AAVrh10 capsid and a vector genome packaged therein, wherein the vector genome comprises an AAV 5? inverted terminal repeat (ITR), a coding sequence for a human Factor IX (F9) having coagulation function operably linked to regulatory elements which direct expression of the human Factor IX in liver cells, and an AAV 3? ITR.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: December 7, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Lili Wang, James M. Wilson
  • Patent number: 11191844
    Abstract: The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: December 7, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Julian Andreev, Nithya Thambi, Frank Delfino, Joel Martin, Gavin Thurston, Katherine Cygnar, Nicholas Papadopoulos
  • Patent number: 11179477
    Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: November 23, 2021
    Assignee: 4D MOLECULAR THERAPEUTICS INC.
    Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
  • Patent number: 11174484
    Abstract: Provided are RNA inhibitory molecules, particularly siRNA molecules silencing the expression of Voltage-Dependent Ion Chanel-1 (VDAC1) for the induction of cancer stem cell differentiation and reduction of TAMs abundance and tumor angiogenesis, thereby preventing tumor invention and recurrence.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: November 16, 2021
    Assignees: B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN- GURION UNIVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
    Inventor: Varda Shoshan-Barmatz
  • Patent number: 11149256
    Abstract: Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain, and lung. The rAAV compositions described herein also have tropisms showing decreased specificity and decreased efficiency of viral transduction in an off-target cell type, for e.g., the liver. The rAAV compositions described herein encapsidate a transgene, such a therapeutic nucleic acid. Upon systemic delivery to a subject, the rAAV is capable of increased specificity and increased transduction of the transgene in a target cell-type, as compared to a parental or reference AAV.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: October 19, 2021
    Assignee: California Institute of Technology
    Inventors: Viviana Gradinaru, Nicholas C. Flytzanis, Nicholas Goeden
  • Patent number: 11091776
    Abstract: Provided herein are AAV8 mutant capsids and rAAV comprising the same. In one embodiment, vectors employing the AAV8 mutant capsid show increased transduction in a selected tissue as compared to AAV8.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: August 17, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Qiang Wang
  • Patent number: 11077156
    Abstract: An adenovirus comprising an E1A polypeptide comprising one or more modifications and comprising an E4orf6/7 polypeptide comprising one or more modifications is described. Compositions and kits comprising the modified adenoviruses are also described. Further described is a method of treating a proliferative disorder in a subject comprising administering to the subject an adenovirus comprising the E1A polypeptide comprising one or more modifications and comprising the E4orf6/7 polypeptide comprising one or more modifications.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: August 3, 2021
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Shigeki Miyake-Stoner
  • Patent number: 11072803
    Abstract: The invention relates to constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5 Kb by using an improved hybrid dual recombinant AAV vector system.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 27, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, UNIVERSITÉ DE MONTPELLIER
    Inventors: Vasiliki Kalatzis, Achille Francois
  • Patent number: 11066648
    Abstract: The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. It further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population, wherein the insulin-producing cell population expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells, and a method for treating a recipient subject suffering from a disease characterized by hyperglycemia with the pharmaceutical composition.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: July 20, 2021
    Assignee: HACKENSACK UNIVERSITY MEDICAL CENTER
    Inventor: Yong Zhao
  • Patent number: 11065284
    Abstract: The present disclosure provides for acid-resistant capsules comprising compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon. Compositions of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: July 20, 2021
    Assignee: Finch Therapeutics Holdings LLC
    Inventor: Thomas Borody
  • Patent number: 11060103
    Abstract: The present invention relates to novel gene sequences encoding insecticidal proteins produced by Bacillus thuringiensis strains. Particularly, new chimeric genes encoding a CryIC, CryIB or CryID protein are provided which are useful to protect plants from insect damage. Also included herein are plant cells or plants comprising such genes and methods of making or using them, as well as plant cells or plants comprising one of such chimeric gene and at least one other such chimeric genes.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 13, 2021
    Assignee: BASF AGRICULTURAL SOLUTIONS SEED, US LLC
    Inventors: Jeroen Van Rie, Frank Meulewaeter, Gerben Van Eldik
  • Patent number: 11060113
    Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof, Lysosomal Membrane Protein 2 (LIMP2), Prosaposin, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: July 13, 2021
    Assignee: Prevail Therapeutics, Inc.
    Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn
  • Patent number: 11045519
    Abstract: An arginine-rich polypeptide composition includes an arginine-rich polypeptide and a pharmaceutically acceptable carrier. Generally, the arginine-rich polypeptide has at least nine arginine residues that represent at least 10% of the amino acid residues in the polypeptide. The arginine-rich polypeptide may be used in a method of inhibiting a human papilloma virus (HPV) from binding to a cell, a method of inhibiting intracellular processing of human papilloma virus (HPV) by a cell, or a method of treating a subject having, or at risk of having, a human papilloma virus (HPV) infection.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: June 29, 2021
    Assignee: UNM Rainforest Innovations
    Inventors: Zurab Surviladze, Michelle A. Ozbun, Andrew Cowan
  • Patent number: 11040082
    Abstract: The present invention relates to methods of treating a patient who has colorectal cancer and to methods of reducing the likelihood that a patient will develop or experience a recurrence of colorectal cancer. The methods comprise a step of introducing, to the patient, an effective amount of an agent that targets an intestinal H+-coupled di/tripeptide transporter (PepT1). Useful compositions including, for example, the tripeptide KPV, vectors encoding such peptides, and cells (e.g., bacterial cells) including them, are also within the scope of the present invention, as are kits including such compositions.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 22, 2021
    Assignees: Georgia State University Research Foundation, Inc., The United States Government as Represented by The Department of Veterans Affairs
    Inventor: Didier Merlin
  • Patent number: 11028131
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 8, 2021
    Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno
  • Patent number: 11020495
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: June 1, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Naxin Tu, Cagan Gurer, Sean Stevens, Andrew J. Murphy
  • Patent number: 11021519
    Abstract: Methods and compositions are provided for intravitreally delivering a polynucleotide to cone photoreceptors. Aspects of the methods include injecting a recombinant adeno-associated virus comprising a polynucleotide of interest into the vitreous of the eye. These methods and compositions find particular use in treating ocular disorders associated with cone dysfunction and/or death.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: June 1, 2021
    Assignees: Adverum Biotechnologies, Inc., University of Washington
    Inventors: Thomas W. Chalberg, Jr., Jay Neitz, Maureen Neitz
  • Patent number: 11020455
    Abstract: There is provided a Colony Stimulating Factor (CSF) as an active ingredient for use in the treatment of colon or pancreatic cancer through an increase in neutrophilia, wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF). The new use for these two recombinant proteins represents a new treatment option for two of the most frequent forms of cancer.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: June 1, 2021
    Assignee: ENDOR TECHNOLOGIES, S.L
    Inventors: Laura Vivero Sánchez, Luciano Sobrevals Amieva, Rafael Miñana Prieto, Judith Sendra Cuadal, Joaquín Querol Sastre
  • Patent number: 11020465
    Abstract: Disclosed herein is a different and novel approach to cancer vaccines using a subject's own dendritic cells (DCs) and macrophages (Mphs) in combination to present cancer antigens to the immune system. Further disclosed are methods of producing monocyte-derived autologous DCs and Mphs loaded ex vivo with particular whole irradiated cancer cells which generates optimally activated immunostimulatory antigen-presenting cells (APCs) as a superior method for stimulating robust and long-lasting immunity to a particular cancer in vivo as compared with more traditional vaccination methods. Compositions, methods of use and methods for preparation of these DCs and Mphs with cancer cells are also disclosed herein.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: June 1, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Gavreel Kalantarov, Ilya Trakht
  • Patent number: 11013755
    Abstract: The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (01). The inhibitors are also useful for inducing an anabolic effect in bone, either alone or when administered in combination with parathyroid hormone or a recombinant fragment thereof. The invention further relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with reduced muscle function, in particular muscle degeneration and muscle atrophy. The inhibitors are also useful for stabilizing and/or strengthening muscle function. In addition, inhibitors of microRNAs 19a and 19b can be used for treating or preventing cancer-related bone destruction or bone metastasis.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: May 25, 2021
    Assignee: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
    Inventors: Eric Hesse, Hanna Taipaleenmäki, Hiroaki Saito
  • Patent number: 11015199
    Abstract: The invention relates to a genetically transformed or transfected bacterial cell chromosome wherein said cell is made to express interfering RNA (siRNA) active against at least one gene encoding a cancer promoting or sustaining protein such as an oncogene, a chemo-resistant gene or a metabolic gene; siRNA cassette encoding at least one siRNA active against said gene; a bacterial cell with said siRNA cassette integrated within the bacterial chromosome; a method of treating cancer, particularly but not exclusively prostate, breast or colorectal cancer, employing the use of said bacterial cell with a chromosomally integrated siRNA cassette; and use of said bacterial cell with a chromosomally integrated siRNA cassette to treat said cancer.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: May 25, 2021
    Assignee: Swansea University
    Inventor: Paul Dyson
  • Patent number: 11007374
    Abstract: Various systems and methods are implemented for controlling stimulus of a cell. One such method is implemented for optical stimulation of a cell expressing an NpHR ion pump. The method includes the step of providing a sequence of stimuli to the cell. Each stimulus increases the probability of depolarization events occurring in the cell. Light is provided to the cell to activate the expressed NpHR ion pump, thereby decreasing the probability of depolarization events occurring in the cell.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: May 18, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Feng Zhang, Edward Boyden
  • Patent number: 11001859
    Abstract: The present invention is directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that are capable of increasing the packaging efficiency of recombinantly-modified adeno-associated virus (rAAV) and their use to improve the packaging efficiency of such rAAV. The present invention is particularly directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that have been further modified to replace (or augment) the P5 and/or P40 promoter sequences that are natively associated with the Rep proteins encoded by such rAAV with AAV P5 and/or P40 promoters that are associated with the Rep proteins of an rAAV of different serotype. The use of such substitute or additional promoter sequences causes increased production of recombinantly-modified adeno-associated virus.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: May 11, 2021
    Assignee: Vigene Biosciences, Inc.
    Inventor: Qizhao Wang
  • Patent number: 11000559
    Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: May 11, 2021
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Brian Robert Champion, Alice Claire Noel Bromley
  • Patent number: 11000590
    Abstract: The present disclosure relates to a composition for transduction of a virus in a cell by using a crosslinked product of PEGylated magnetic nanoparticles and catechol grafted poly-L-lysine by application of an external magnetic field. When the composition is used, a virus may be delivered into cells more rapidly and efficiently than in intracellular uptake of a virus by CAR-mediated endocytosis.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: May 11, 2021
    Assignee: GENEMEDICINE CO., LTD.
    Inventors: Chae Ok Yun, Joung-Woo Choi
  • Patent number: 10994009
    Abstract: A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/?4?1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing ?4?1.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: May 4, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Alex Yee-Chen Huang, Jay T. Myers
  • Patent number: 10993972
    Abstract: Provided are: a transformation plasmid for transforming anaerobes and enabling highly efficient and stable secretory expression of a target protein; a gene delivery carrier formed from said anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these. Also provided are: a novel secretory signal; a transformation plasmid including said secretory signal; a gene delivery carrier formed from anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: May 4, 2021
    Assignees: Shinshu University, Anaeropharma Science, Inc.
    Inventors: Yuko Wada, Yuko Shimatani, Takashi Yano, Takeshi Masaki
  • Patent number: 10980859
    Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: April 20, 2021
    Assignee: Hangzhou Converd Co., Ltd.
    Inventors: Fang Hu, Ronghua Zhao, Siyi Chen, Bo Wu, Huiqun Xia, Yanjun Zheng